Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Pamela Degendorfer"'
Autor:
Amit M. Oza, Lawrence Kasherman, Shahid Husain, Ann Heesters, Wei Xu, Pamela Degendorfer, Katherine Karakasis, Ainhoa Madariaga
Publikováno v:
Medicinal Research Reviews. 41:725-738
Public Health Emergencies of International Concern, such as the coronavirus disease 2019 pandemic, have a devastating impact on an individual and societal level, and there is an urgent need to learn, understand and bridge the therapeutic gap at a tim
Autor:
Pamela Degendorfer, Hal W. Hirte, Amit M. Oza, Gregory R. Pond, Malcolm J. Moore, Glenwood D. Goss, Lillian L. Siu, Carol A. Townsley, Eric Winquist
Publikováno v:
Clinical Cancer Research. 12:2141-2149
Background: The tolerability of molecularly targeted agents in older patients has not been specifically examined. Adverse event data from clinical trials in the Princess Margaret Hospital Phase II Consortium database were analyzed to address this que
Publikováno v:
Journal of Clinical Oncology. 35:189-189
189 Background: The clinical research environment is consistently evolving with new methodology, complexity and regulatory stringency. With this evolution, the need for a well-educated clinical research team is critical. There are approximately 300 c
Autor:
Susanna Sellmann, Jennifer S. Li, Lindsay Philip, Cristina Guglielmi, Amit M. Oza, Pamela Degendorfer
Publikováno v:
Journal of Clinical Oncology. 34:274-274
274 Background: Quality assurance (QA) in clinical trials is a safeguard against non-compliance, which impacts patient safety and data integrity. On an institutional level, compiling quality findings provides insight to gaps within existing processes
Autor:
Pamela Degendorfer, John J. Wright, Eric Winquist, Walter M. Stadler, Greg Pond, Gonzalo Gomez-Abuin, Malcolm J. Moore
Publikováno v:
Investigational new drugs. 25(2)
Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of bortezomib [PS-341], a reversible proteasome inhibitor, for patients with advanced or m
Autor:
Grace Eagan, Pamela Degendorfer, Lindsay Philip, Amit M. Oza, Jasmine Grant, Elizabeth Abraham
Publikováno v:
Journal of Clinical Oncology. 32:189-189
189 Background: Toronto is a multicultural city with over 160 languages spoken by patients. Since 2010, institutional policy requires that professional medical interpreters are used when obtaining informed consent from patients with limited English p
Autor:
Lindsay Philip, Aaron Di Nardo, Marcia Flynn-Post, Heather Cole, Calven Eggert, Leslie Williams-Brennan, Susanna Sellmann, Jasmine Grant, Pamela Degendorfer
Publikováno v:
Journal of Clinical Oncology. 32:e17613-e17613
153 Background: As trial complexity increases, there is a growing need to facilitate rapid communication of trial data among members of the research and clinical care teams. Timeliness of investigator review and high quality data are critical to clin
Autor:
Daniela Trapsa, Diane Arndt, Mary J. MacKenzie, Amit M. Oza, Laureen Johnson, Patricia A. Tang, Stephen Welch, Cindy Y. F. Yau, Poornima Dhobe, Carol A. Townsley, Desiree Hao, Pamela Degendorfer, Quincy Chu, Sujay Kulkarni, Gajendra Jawlekar, Jennifer L. Spratlin
Publikováno v:
Journal of Clinical Oncology. 30:3013-3013
3013 Background: P1446A-05 is a novel oral inhibitor of Cdk4-D1, Cdk1-B, and Cdk9-T, and has been shown to inhibit tumor growth both in vitro and in vivo. Pharmacodynamic studies demonstrate that activation of Cdk1 reappears within 48 hours after P14
Autor:
A. M. Oza, Pamela Degendorfer, Susanna Sellmann, J. Brown, Tony Panzarella, Heather Cole, L. M. Tinker, Mary Gospodarowicz
Publikováno v:
Journal of Clinical Oncology. 29:e16572-e16572
e16572 Background: Quality assurance (QA), efficient timelines, improving risk management and cost effectiveness are critical to the clinical trials (CT) in academic centers in the current economic climate. Site selection is highly competitive and ma
Autor:
L. M. Tinker, S. J. Webster, Pamela Degendorfer, J. Brown, B. Fitzgerald, Heather Cole, Susanna Sellmann, Tony Panzarella
Publikováno v:
Journal of Clinical Oncology. 29:e16577-e16577
e16577 Background: Deficiencies pertaining to the accuracy, completeness and maintenance of source data remain the most prevalent regulatory finding reported during site inspections. The Princess M...